Anti–protein Z antibodies in women with pathologic pregnancies-Reference-Cited by-同舟云学术

Anti–protein Z antibodies in women with pathologic pregnancies

Published:2003-06-15 Issue:12 Volume:101 Page:4850-4852
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Gris Jean-Christophe¹,Amadio Cécile¹,Mercier Eric¹,Lavigne-Lissalde Géraldine¹,Déchaud Hervé¹,Hoffet Médéric¹,Quéré Isabelle¹,Amiral Jean¹,Dauzat Michel¹,Marès Pierre¹

Affiliation:

1. From the Laboratoire d'Hématologie, Unité de Formation et de Recherche (UFR) des sciences pharmaceutiques et biologiques, Université Montpellier 1, Montpellier, France; Laboratoire d'Hématologie, Centre Hospitalier Universitaire (CHU) de Nîmes, France; the EA 2992 (“Dynamique des incohérences cardiovasculaires”), Nîmes, France; the Département de Gynécologie et Obstétrique, CHU de Nîmes, France; and Hyphen BioMed, Andrésy; France.

Abstract

Abstract Protein Z deficiencies have recently been described in women with unexplained early fetal loss. Using a new, specifically elaborated, commercially available enzyme-linked immunosorbent assay (ELISA), we performed a case-control study on anti–protein Z immunoglobulin G (IgG) and IgM antibodies in 191 nonthrombotic, nonthrombophilic women with consecutive pathologic pregnancies. Levels of anti–protein Z antibodies were categorized in 3 strata (percentiles 1 through 74, 75 through 97, 98 through 100 among controls). The 2 upper levels of IgG and IgM anti–protein Z antibodies were associated with the risk of unexplained recurrent embryo loss or fetal death independently from habitual antiphospholipid/anticofactor antibodies, and a dose-effect relationship between antibody levels and the clinical risks was evidenced. In women, enhanced immune-complex formation with protein Z may play a role in unexplained embryo losses and, from the 10th week of gestation, may favor hypercoagulability in the maternal placenta side.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/101/12/4850/1687813/h81203004850.pdf

Reference8 articles.

1. Han X, Huang ZF, Broze GJ Jr. Characterization of protein Z-dependent protease inhibitor. Blood. 2000;96: 3049-3055.

2. Broze GJ Jr. Protein Z-dependent regulation of coagulation. Thromb Haemost. 2001;86: 8-13.

3. Gris JC, Quéré I, Déchaud H, et al. High frequency of protein Z deficiency in patients with unexplained early fetal loss. Blood. 2002;99: 2606-2608.

4. Gris JC, Ripart-Neveu S, Maugard C, et al Prospective evaluation of the prevalence of haemostasis abnormalities in unexplained primary early recurrent miscarriages: The Nîmes Obstetricians and Haematologists Study (NOHA). Thromb Haemost. 1997;77: 1096-1103.

5. Gris JC, Quéré I, Monpeyroux F, et al. Casecontrol study of the frequency of thrombophilic disorders in couples with late foetal loss and no thrombotic antecedent: the Nîmes Obstetricians and Haematologists Study5 (NOHA5). Thromb Haemost. 1999;81: 891-899.

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Generation and pathogenicity of autoantibodies associated to thrombosis and hemostasis;Exploration of Immunology;2024-02-05

2. Autoimmune clotting dysfunction;The Rose and Mackay Textbook of Autoimmune Diseases;2024

3. An update on anti-protein Z antibodies;Exploration of Immunology;2023-12-05

4. Autoimmune Clotting Dysfunction;The Autoimmune Diseases;2020

5. High frequency of anti-protein Z antibodies in patients with anticardiolipin antibodies;Immunobiology;2018-12